Patents by Inventor Satomi Miki

Satomi Miki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AUTOPHAGY ACTIVATING AGENT
    Publication number: 20210228521
    Abstract: To provide a compound used for activating autophagy, which has few side effects and mild effects. An autophagy activating agent comprising S1PC or a salt thereof as an active ingredient.
    Type: Application
    Filed: June 6, 2019
    Publication date: July 29, 2021
    Applicant: WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Junichiro SUZUKI, Yukihiro KODERA, Satomi MIKI
  • METHOD OF EVALUATING COMPOUND EFFICACIOUS IN TREATING OBESITY BY USING Slc25a10
    Publication number: 20100076059
    Abstract: Evaluation of compounds including screening of therapeutic agents for obesity is performed utilizing expression levels of S1c25a10 gene or protein in a test tissue or a test cell, or utilizing the nature of S1c25a10 gene or protein. Examination of obesity is performed based on expression levels of S1c25a10 gene or polymorphisms of the gene.
    Type: Application
    Filed: October 28, 2009
    Publication date: March 25, 2010
    Inventors: HIDEHITO KOTANI, Hiraku Itadani, Shinji Mizuarai, Hiromitsu Araki, Satomi Miki
  • Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor
    Publication number: 20100022404
    Abstract: [PROBLEMS] To provide: a gene marker or a protein marker for detecting whether or not an Aurora A inhibitor acts in a living body in an Aurora A-specific manner when the Aurora A inhibitor is administered to the living body; and a method for predicting or diagnosing the pharmacological efficacy of an Aurora A inhibitor by using the gene marker or the protein marker [MEANS FOR SOLVING PROBLEMS] A gene/protein marker for use in the prediction or diagnosis of the pharmacological efficacy of an Aurora A inhibitor, wherein the gene is a gene selected from the group consisting of Aurora B, Histone H3, BIRC5, PRC1, DLG7, TACC3 and KNTC2 or a gene having substantially the same function as that of the gene; and a method for predicting or diagnosing the pharmacological efficacy of an Aurora A inhibitor by using the gene/protein marker.
    Type: Application
    Filed: October 5, 2007
    Publication date: January 28, 2010
    Inventors: Shinichi Hasako, Koji Ichikawa, Hideto Kotani, Satomi Miki, Katsuyoshi Miyama, Toshiyasu Shimomura, Kazuhiko Takahashi, Kazunori Yamanaka
  • Method of evaluating compound efficacious in treating obesity by using slc25a10
    Publication number: 20060198788
    Abstract: Evaluation of compounds including screening of therapeutic agents for obesity is performed utilizing expression levels of Slc25a10 gene or protein in a test tissue or a test cell, or utilizing the nature of Slc25a10 gene or protein. Examination of obesity is performed based on expression levels of Slc25a10 gene or polymorphisms of the gene.
    Type: Application
    Filed: July 27, 2004
    Publication date: September 7, 2006
    Inventors: Hidehito Kotani, Hiraku Itadani, Shinji Mizuarai, Hiromitsu Araki, Satomi Miki